Objective: The axis of apolipoprotein M (apoM) and sphingosine-1-phosphate (S1P) is of importance to 24 plasma lipid levels, endothelial function, and development of atherosclerosis. Menopause is accompanied by 25 dyslipidemia and an increased risk of atherosclerosis, which can be lowered by exercise training. The aim of 26 this study was to explore if effects of menopause and training are paralleled by changes in the apoM/S1P 27
Introduction 53
Menopause is associated with an elevated risk of developing endothelial dysfunction (33) and metabolic 54 syndrome, including dyslipidemia and atherosclerosis (7). Long-term hormone therapy is not generally 55 recommended for postmenopausal women due to increased risk of cancer and athero-thrombotic disease 56 (32). Currently, there is a lack of mechanistic understanding of changes that cause dyslipidemia, 57 atherosclerosis, and endothelial dysfunction in postmenopausal women. 58
Apolipoprotein M (apoM) is a lipocalin mainly bound to plasma high density lipoprotein (HDL) 59 particles (11). ApoM has an important role in protecting the endothelial barrier function (8, 12) and affects 60 several potential anti-atherogenic pathways, such as reverse cholesterol transport (10, 19), formation of preβ-61 HDL (10, 34, 47), and removal of reactive oxygen species (10, 18). Moreover, variations in the apoM gene 62 are associated with risk of cardiovascular disease (CVD) and altered plasma lipids (5). Further investigations 63 are however needed to clarify the exact role of apoM in atherosclerosis and dyslipidemia. 64
The bioactive lipid sphingosine-1-phosphate (S1P) is carried by apoM (12). ApoM-containing HDL 65 carries ~65 % of plasma S1P, while albumin carries ~35 % (27, 35). Hence, apoM is a chaperone, and its 66 biological effects are likely provided by S1P (36, 40). S1P acts through five G-protein-coupled receptors 67 (S1P r1-5 ) (24), affecting diverse processes such as protection of the endothelial barrier (8, 12, 45), regulation 68 of angiogenesis (16), promotion of lymphocyte trafficking (39), and activation of endothelial nitric oxide 69 synthase (eNOS) (23). Accordingly, S1P has been implicated in several diseases, including inflammatory 70 diseases and atherosclerosis (30) . 71
Exercise training decreases CVD risk by effects on endothelial function (21) and plasma lipids, 72 including in postmenopausal women (4, 28, 42 ). This finding is of particular interest as the menopausal 73 transition is accompanied by increased prevalence of dyslipidemia (7, 14, 15, 25) , and endothelial 74 dysfunction (33). The apoM/S1P axis is associated with endothelial function (8, 12) and plasma lipids (5), 75 which are all influenced negatively by the menopausal transition and can be improved with exercise training. 76
The effect of menopause and exercise training on the apoM/S1P axis itself is unknown, and further 77 investigation is needed in order to understand if apoM and S1P are involved in menopausal and exercise-78 induced changes. This has prompted the present study on how plasma apoM and S1P concentrations are 79 6
Materials and methods 84
The data presented in this study are part of the Copenhagen Women Study (31, 37), which is an 85 interdisciplinary study on the effects of exercise training in the late premenopausal and early postmenopausal 86 phase. The study was approved by the Ethics Committee in the capital region of Denmark (protocol number: 87 H-1-2012-150) and hosted institute. All participants were given informed consent at time of inclusion, and 88 the study was conducted in accordance with the guidelines of the Declaration of Helsinki. 89
Participants -In the present study, we used samples from 38 premenopausal women and 37 postmenopausal 90 women from the Copenhagen Women Study (31, 37). All included participants were healthy non-smokers 91 with no excessive alcohol intake and a body mass index of 18.5-30 kg/m 2 . The premenopausal women had 92 regular menstrual cycles and were not using hormonal contraceptives. The postmenopausal women had not 93 experienced a menstrual cycle for at least 1 year and were not receiving hormone therapy. All women were 94 physically active less than 2 hours per week prior to the training intervention. 95 Study design -As described previously (31, 37), all women underwent testing before and after three months 96 of high-intensity exercise training on a cycling ergometer for one hour three times per week. The training 97 sessions were supervised by instructors, and exercise intensity was monitored and increased gradually during 98 the three-month period. As described by Nyberg et al (37), the heart rate was at 71-95% of the maximal heart 99 rate almost 90% of the time. On test days, all women were fasting and had not exercised for 24 hours. Hoffmann-La Roche Ltd., Rotkreuz, Switzerland). Other blood samples for apoM and S1P measurements 105 were centrifuged for 5 minutes at 4000g and stored at -80°C. Blood samples for S1P measurements were 106 placed on ice immediately after collection. Statistical Analysis -Data were analyzed using GraphPad Prism 4 software. The significance level (alpha) 119 was set at p<0.05. The effects of menopausal status and exercise training were assessed using two-way 120 repeated measures ANOVA; only women with measurements before and after the training intervention were 121 included in the two-way repeated measures ANOVA. Correlations were assessed using Pearson correlation 122 analysis. Normally distributed data are presented as mean±SD. Data that are not normally distributed are log-123 transformed and presented as median (25-75 percentile). After the log-transformation, all data were normally 124
distributed. 125

Results 127
Characteristics of the participants -Before the training intervention, the premenopausal women were 49.2±2 128 years old. The postmenopausal women were 53.3±3 years old and 3.1±1 years past their final menstruation. 129
Effects of menopausal status -Before training, the plasma apoM concentration was 32 % higher in the 130 postmenopausal than in the premenopausal women (1.08±0.2 µmol/l and 0.82±0.2 µmol/l, respectively) 131 (p<0.0001) ( Figure 1A ). The plasma S1P concentration was similar in the two groups (p>0.05) ( Figure 1B) . 132
Hence, the S1P/apoM ratio was 26 % lower in postmenopausal than premenopausal women before training 133 (0.45±0.1 and 0.61±0.2, respectively) (p<0.001) (Figure 2A ). In accordance with previous findings from the 134
Copenhagen Women Study (40), plasma TC (p<0.0001), HDL-C (p<0.001), and LDL-C (p<0.01) 135 concentrations were higher in this subset of postmenopausal compared with premenopausal women, while 136 the plasma triglyceride concentration was similar in the two groups (p>0.05) ( Table 1 ). The plasma 137 apoM/HDL-C ratio was also similar in the two groups (p>0.05) ( Figure 2B ). Table 1 ). The plasma apoM/HDL-C ratio was increased from 0.50±0.1 to 0.54±0.2 in 146 premenopausal women and from 0.56±0.2 to 0.60±0.2 in postmenopausal women, which was borderline 147 statistically significant (p=0.05) ( Figure 2B) . 148
Correlations between apoM and lipids in plasma -The plasma apoM concentration correlated positively 149 with plasma TC, HDL-C, and LDL-C concentrations both before and after the training intervention, while no 150 correlation was found between the plasma apoM and triglyceride concentration (Figure 3) . Also, there was 151 9 no correlation between plasma apoM and S1P concentrations (p>0.05) (Figure 4) . Additionally, plasma S1P 152 concentrations did not correlate with plasma TC, HDL-C, LDL-C, or triglyceride concentrations (p>0.05) 153 (data not shown). 154
Discussion 155
There were two main findings in the present study. Firstly, recent postmenopausal women had higher 156 plasma apoM than late premenopausal women. Secondly, exercise training increased plasma apoM and S1P 157 in both late premenopausal and recent postmenopausal women. 158
Recent postmenopausal women had 32 % higher plasma apoM concentrations compared with late 159 premenopausal women before the training intervention. There are at least two possible explanations for this. 160
The first possible explanation for the higher postmenopausal apoM concentration is a difference in lipid 161 levels. The postmenopausal women had higher TC (by 15 %), HDL-C (by 21 %), and LDL-C (by 14 %) 162 compared with the premenopausal women before the training intervention. In accordance with previous 163 findings, apoM correlated positively with plasma TC, HDL-C, and LDL-C (1). ApoM also correlates 164 negatively with the fractional catabolic rate of LDL (9), suggesting that LDL-C should be increased when 165 apoM is increased, which is consistent with our findings. As discussed previously (31), there is a general 166 agreement that TC and LDL-C are elevated in postmenopausal women compared with premenopausal 167 women, rendering a more atherogenic profile (7, 14, 25). In contrast, findings on the relationship between 168 menopause and HDL-C and triglycerides are inconsistent (7, 14, 15, 25, 38). The Study of Women's Health 169
Across the Nation (SWAN) found that HDL-C was higher in recent postmenopausal women (<24 months 170 after the final menstrual period [FMP] ), but then declined to the premenopausal level in late postmenopausal 171 women (>24 months after the FMP) (14). In the present study, no significant correlation between lipid levels 172 or apoM levels and age was found (data not shown). A study on a sub-cohort from SWAN also found that an 173 increase in HDL-C over the menopausal transition was associated with a greater development of 174 atherosclerosis (17). This is an interesting observation as HDL particles are generally considered anti-175 atherogenic (20). The finding that plasma apoM was higher in the postmenopausal women might be 176 explained by a concomitant increase in HDL-C, illustrated by a stable apoM/HDL-C ratio between pre-and 177 postmenopausal women. Thus, one may speculate that apoM-containing HDL particles may lose their 178 endothelium-protective and anti-atherogenic potential over the menopausal transition. Nyberg et al., found 179 that the early postmenopausal phase was associated with a marked reduction in vascular function in the 180
Copenhagen Women Study (37), and observed that several biomarkers of vascular function were adversely 181 altered in a similar cohort (38). Further studies are however still needed to conclude whether apoM-182 containing HDL plays a role in this reduction. Second, it is possible that the higher apoM concentration can 183 be explained by the changes in hormone levels that occur over the menopausal transition and possibly even a 184 direct effect of sex hormones on apoM. Axler et al. found that apoM concentrations correlate positively with 185 age for women only, with women aged 18-49 years having lower apoM concentrations than women aged 50 186 years or older (1). This observation does not prove a link between apoM and menopause, but the study 187 supports the notion that apoM concentrations could be dependent on hormone levels, as the positive 188 correlation with age is seen for women only. Few studies have addressed the effect of sex hormones on 189 apoM, but it has been shown that estrogen upregulates apoM expression in vitro and in vivo in rats (44). This 190
suggests that plasma apoM concentrations should be higher in pre-than postmenopausal women, which was 191 not the case in the present study. Further, we did not find any correlation between levels of estrogen and 192
apoM (data not shown). Thus, present findings suggest that the difference in apoM levels between groups 193
may not be related to estrogen alone, but rather to a combination of age, hormonal status, and other unknown 194
variables. 195
Plasma S1P was similar in pre-and postmenopausal women, causing the S1P/apoM ratio to be 196 significantly lower in postmenopausal women. A recent study found that apoM without S1P did not have 197 anti-inflammatory properties (41); this further supports the notion that the higher apoM concentrations in 198 postmenopausal women do not necessarily provide an atheroprotective effect as the S1P concentration did 199 not differ between the two groups. This finding is in contrast to an earlier study which found that plasma S1P 200 in premenopausal women. The study found S1P to be negatively correlated with age in both men and women 201 (22). A disadvantage of the study is a large age difference between the subjects (~30 years), and lack of 202 follow up on the same subject before, during, and after postmenopausal transition. While the Copenhagen 203
Women Study neither is a prospective study, it has the strength of a minimal age difference (~4 years) 204 between the two groups. In the future, it would be relevant to examine the effect of menopause on the 205 apoM/S1P axis by following the same cohort throughout the menopausal transition since the pre-menopausal 206 women in the present study could be at varies pre-transitional ages. 207
12
The training intervention increased plasma apoM and plasma S1P. Importantly, the S1P/apoM ratio 208 did not change in contrast to the menopause-related changes, implying that the training-induced increase is 209 different from and possibly renders a more atheroprotective profile than the menopause-induced changes. 210 There are at least two possible explanations for the post-training increase in apoM. First, it is possible that 211 the exercise-induced changes can be explained by changes in plasma lipids. The general consensus is that 212 exercise training increases HDL-C in healthy adults, providing an atheroprotective effect (13, 29). However, 213 previous findings in postmenopausal women have shown that exercise training decreases TC and LDL-C 214 without changing HDL-C (4), which is in accordance with the present findings. Thus, it does not seem likely 215 that the post-training increases in apoM and S1P can be explained solely by changes in plasma lipids. 216
Another possible explanation could be that training also lowered plasma insulin during the oral glucose 217 tolerance test (31) which could lead to an increase in plasma apoM as insulin inhibits the expression of apoM 218 through a Foxa2-mediated mechanism (46). The increase in S1P with training agrees with a previous study 219
showing that plasma S1P was 37 % higher in endurance trained (average experience of 4.3±1.7 years of long 220 distance running) than in untrained healthy, young males (2). However, another study found no difference in 221 plasma S1P between endurance-trained athletes and obese, sedentary controls (3). The reason for this 222 discrepancy between studies is unclear, but the variation may be due to differences in study setups, including 223 gender, age, and duration of the training period. 224
Potential Clinical Value -Currently, there is a lack of mechanistic understanding of changes that occur 225 during the menopausal transition. Also, few intervention studies have been conducted addressing the effects 226 on plasma apoM levels in humans. One study has shown that 8 weeks of statin treatment decreases apoM by 227 7% (26). In the present study the range of changes are comparable observed between pre-and 228 postmenopausal women. However, the higher apoM in postmenopausal women without a concomitant 229 increase in S1P may contribute to understanding how previously atheroprotective apoM-containing HDL 230 particles can lose their anti-atherogenic and endothelium-protective potential in the menopausal transition. 231
The finding that postmenopausal women have a lower S1P/apoM ratio gives rise to the question of whether 232 S1P analogues -which are currently released on the market for treatment of multiple sclerosis (43) -can be 233 13 beneficial in treating risk factors for endothelial dysfunction and atherosclerosis related to the 234 postmenopausal phase. Finally, exercise increased both plasma apoM and S1P in pre-and postmenopausal 235 women. It is likely that an extended period of training could increase the plasma apoM/S1P levels further. To 236 maintain a high level of apoM -and S1P containing HDL particles could be of clinical value due to its anti-237 atherogenic and endothelial protective value. Data were evaluated by Pearson´s correlation. ApoM, apolipoprotein M; S1P, sphingosine-1-phosphate. 404 Tables  405   Table 1 
